David Sans
Healthcare and Finance Leader
Dr. Sans is an accomplished corporate development executive with robust scientific and medical expertise. David Sans currently serves as Director of Healthcare at D. Boral in New York City, where he oversees all Healthcare Transactions at D. Boral Capital spearheading and driving a wide range of industry transactions.
Prior to joining EF Hutton, Dr. Sans served as Head of Corporate Development at Calidi Technologies, where he led the corporate development function and supported activities with strategic partners, including identification, assessment and execution of potential mergers, acquisitions, investments, licensing agreements, and joint ventures. Before that, Dr. Sans served as Head of Healthcare Investment Banking at ThinkEquity, where he provided a full range of investment banking advisory services and completed over 100 transactions with an aggregate value of over $10 billion. Prior to ThinkEquity, he founded the AI Pathology platform at Mount Sinai Hospital, where he built a corporate function dedicated to co-founding companies with external inventors, providing crossover investment capital and expertise to originate early-stage ventures in the life sciences field through IPO. Previously, Dr. Sans held corporate development roles at Exact Sciences and ImClone Systems. He began his career working for large pharmaceutical companies, serving as Head of Market Analytics at Pfizer, Inc., supporting the commercial launch of Rebif® and Macugen® and Lead Sr. Scientist at Novartis AG, supporting the launch of Glibec®.
Dr. Sans is a member of the Cancer Moonshot committee, an initiative led by President Biden and the First Lady aimed to inspire and support the next generation of world-class and diverse scientists and health innovators focused on breakthroughs that will make a difference for patients and drive progress. David is tasked to review and supervise medical and research programs.
David Sans is an advisor at the Cancer Prevention & Research Institute of Texas, Anixa Biosciences and the 2020 Cancer Moonshot.
David holds a Ph.D. in Chemical Engineering from Universtiat Ramon Llul in collaboration with the ETH in Zürich, and an MBA in Business Law from Fordham University. He also holds a Mount Sinai Board Certification in Cell Therapies and a Fellowship in Anti-Aging and Regenerative Medicine (FAARM).
Advisory Boards
Cancer Prevention & Research Institute of Texas
David Sans serves as an advisor for CPRIT, a state agency that funds cancer research in Texas. Researchers and organizations in Texas are invited to apply for grants that match CPRIT's mission.
CPRIT’s goals are to 1) create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of cancer and cures for cancer; 2) attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in this state; and 3) develop and implement the Texas Cancer Plan.
Anixa Biosciences
David Sans serves as a business and corporate development advisor at Anixa Biosciences, a biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company’s vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer, as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer.
Cancer Moonshot
David Sans serves in the advisory committee of the Cancer Moonshot program, initiative led by President Biden and the First Lady aimed to inspire and support the next generation of world-class and diverse scientists and health innovators focused on breakthroughs that will make a difference for patients and drive progress.
Cancer touches every American in some way, and is still the second leading cause of death in America despite the progress we’ve made in recent decades. By bringing together the federal government, health care providers, researchers, patients, caregivers, advocates, and the public and private sectors, the Cancer Moonshot is dramatically accelerating progress against cancer.
The Cancer Moonshot is mobilizing efforts toward achieving two clear goals that the President and First Lady set: To prevent more than 4 million cancer deaths by 2047 and to improve the experience of people who are touched by cancer.
David Sans in the news
EF Hutton appoints David Sans as Head of Healthcare
Titan Partners Group Announces Addition of Dr. David Sans as Head of Healthcare
Calidi Biotherapeutics Appoints David Sans, FAARM, Ph.D., MBA, As Head Of Corporate Development
XORTX Appoints Dr. David Sans in New York as Director Corporate Development
Let’s Connect!
David is always looking to partner with CEOs from high growth and special situation micro and small cap public companies looking to raise capital, buy and sell side advisory and general financial advisory.